Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We’re driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. We are focussing all of our activities and efforts on moving towards our vision of a world free of pain.
“Although few people die of pain, many still die in pain, while even more live in pain. We will leave no stone unturned to help these patients.”
As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to people living with pain worldwide. Strong ongoing partnerships with leading healthcare and development organisations bring our new products to life. We’re a fully integrated pharmaceutical company that offers support along the entire value chain – from drug development through to commercialisation.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 30 countries across Europe, Latin America and the US. Our products are sold in more than 100 countries. In 2018, Grünenthal employed around 4,900 people and achieved sales of € 1.3 billion.
billion euro in 2018
countries across Europe, Latin America and the US
R&D hubs in Aachen, Mexico City, Morristown and Boston
manufacturing sites in Europe and Latin America